Cytokine and Metabolomic Signatures of Mepolizumab Response Across Upper and Lower Airway Compartments in Severe Eosinophilic Asthma: An Exploratory Analysis
<b>Background</b>: Mepolizumab improves asthma control in severe eosinophilic asthma (SEA). However, its multidimensional effects on airway and systemic biomarkers are still incompletely understood. <b>Methods</b>: In this prospective study, 15 SEA patients were evaluated at baseline (T<sub>0</sub>), 6 (T<sub>6</sub>), and 12 months (T<sub>12</sub>) after starting mepolizumab. Lung function, FeNO values, asthma control, blood eosinophil count (BEC), cytokines, and metabolomic profiles (<sup>1</sup>H-NMR) were evaluated in serum, nasal secretions, and exhaled breath condensate (EBC). Univariate and multivariate (PCA, OPLS-DA) analyses were performed. <b>Results</b>: Mepolizumab reduced exacerbations, from a median of 2 at T<sub>0</sub> to 0 at both T<sub>6</sub> (<i>p</i> = 0.001) and T<sub>12</sub> (<i>p</i> = 0.003). ACT improved from 18.7 ± 4.7 at baseline to 23.0 ± 2.8 at T<sub>6</sub> (<i>p</i> = 0.026) and 23.4 ± 3.3 at T<sub>12</sub> (<i>p</i> = 0.032), while FEV<sub>1</sub> increased by 270 mL at T<sub>6</sub> (<i>p</i> = 0.032) and remained stable at T<sub>12</sub>. Median BEC decreased from 450.0 (350.0-560.0) to 65.0 (50.0-87.5) cells/μL at T<sub>6</sub> and to 50.0 (35.0-160.0) at T<sub>12</sub> (<i>p</i> < 0.001), while FeNO showed a non-significant downward trend. IL-13 significantly decreased in serum and nasal secretions at T<sub>6</sub> and T<sub>12</sub>, while IL-5 increased in nasal secretions at both timepoints and remained unchanged in serum. IL-2 showed opposite trends in serum and nasal samples, whereas GM-CSF and IFN-γ increased in nasal secretions at T<sub>12</sub>. Metabolomic profiling suggested compartment-specific changes, with decreased short-chain alcohols in EBC, increased amino acids in nasal secretions and serum at T<sub>6</sub>, and elevated pyruvate in serum at T<sub>12</sub>, although none reached statistical significance in univariate analysis. <b>Conclusions</b>: Mepolizumab induced consistent clinical, immunologic, and metabolic changes across compartments, supporting the use of integrated cytokine and <sup>1</sup>H-NMR metabolomic profiling as a complementary approach for response assessment in SEA.
Authors
- Claudio Candia (ORCID: https://orcid.org/0000-0002-5888-8781)
- Nicolino Ambrosino (ORCID: https://orcid.org/0000-0002-5331-1393)
- Isabella Gnemmi (ORCID: https://orcid.org/0000-0003-0045-6369)
- Martina Zappa (ORCID: https://orcid.org/0000-0001-8443-5316)
- Pasquale Ambrosino (ORCID: https://orcid.org/0000-0002-9398-0428)
- Dina Visca (ORCID: https://orcid.org/0000-0003-2298-1623)
- Andréa Motta (ORCID: https://orcid.org/0000-0002-8643-658X)
- Antonino Di Stefano (ORCID: https://orcid.org/0000-0003-3479-0875)
Institutions
- University of Insubria (IT)
- Istituti Clinici Scientifici Maugeri (IT)
- Federico II University Hospital (IT)
- National Research Council (IT)
- University of Palermo (IT)
Publication Details
- Journal
- Pharmaceuticals
- Published
- 2025-11-10
- DOI
- https://doi.org/10.3390/ph18111704
- Citations
- 1
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 1.16